Persistently elevated expression of systemic, soluble co-inhibitory immune checkpoint molecules in people living with HIV before and one year after antiretroviral therapy
- UPSpace Home
- →
- Health Sciences
- →
- Internal Medicine
- →
- Research Articles (Internal Medicine)
- →
- View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.
Please note that UPSpace will be unavailable from Friday, 2 May at 18:00 (South African Time) until Sunday, 4 May at 20:00 due to scheduled system upgrades. We apologise for any inconvenience this may cause and appreciate your understanding.
| dc.contributor.author | Labuschagne Naidoo, Robyn-Brooke
|
|
| dc.contributor.author | Steel, Helen C.
|
|
| dc.contributor.author | Theron, Annette J.
|
|
| dc.contributor.author | Anderson, Ronald
|
|
| dc.contributor.author | Tintinger, Gregory Ronald
|
|
| dc.contributor.author | Rossouw, Theresa M.
|
|
| dc.date.accessioned | 2025-04-08T13:21:51Z | |
| dc.date.available | 2025-04-08T13:21:51Z | |
| dc.date.issued | 2024-06 | |
| dc.description | DATA AVAILABILITY STATEMENT: The data that support the findings of this study are available from the corresponding author upon reasonable request. | en_US |
| dc.description | SUPPORTING INFORMATION: TABLE S1: Comparison of soluble immune checkpoint levels between female and male PLWH before ART; TABLE S2: Comparison of soluble immune checkpoint levels between female and male PLWH after 12 months of ART; TABLE S3: Comparison of the change in soluble immune checkpoint levels before and after 12 months of ART between tobacco-users and non-users; TABLE S4: Correlations between age and soluble immune checkpoint molecules before treatment in PLWH. | en_US |
| dc.description.abstract | Please read abstract in article. | en_US |
| dc.description.department | Immunology | en_US |
| dc.description.department | Internal Medicine | en_US |
| dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
| dc.description.sdg | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.description.uri | https://www.mdpi.com/journal/pathogens | en_US |
| dc.identifier.citation | Labuschagne Naidoo, R.-B.; Steel, H.C.; Theron, A.J.; Anderson, R.; Tintinger, G.R.; Rossouw, T.M. Persistently Elevated Expression of Systemic, Soluble Co-Inhibitory Immune Checkpoint Molecules in People Living with HIV before and One Year after Antiretroviral Therapy. Pathogens 2024, 13, 540. https://doi.org/10.3390/pathogens13070540. | en_US |
| dc.identifier.issn | 2076-0817 (online) | |
| dc.identifier.other | 10.3390/pathogens13070540 | |
| dc.identifier.uri | http://hdl.handle.net/2263/101927 | |
| dc.language.iso | en | en_US |
| dc.publisher | MDPI | en_US |
| dc.rights | © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an Open Access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/). | en_US |
| dc.subject | Antiretroviral treatment | en_US |
| dc.subject | Co-inhibitory immune checkpoints | en_US |
| dc.subject | CTLA-4 | en_US |
| dc.subject | LAG-3 | en_US |
| dc.subject | PD-1 | en_US |
| dc.subject | PD-L1 | en_US |
| dc.subject | TIM-3 | en_US |
| dc.subject | SDG-03: Good health and well-being | en_US |
| dc.subject | SDG-09: Industry, innovation and infrastructure | en_US |
| dc.subject | Antiretroviral therapy (ART) | en_US |
| dc.subject | Human immunodeficiency virus (HIV) | en_US |
| dc.title | Persistently elevated expression of systemic, soluble co-inhibitory immune checkpoint molecules in people living with HIV before and one year after antiretroviral therapy | en_US |
| dc.type | Article | en_US |
